These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 16805746)
1. Treatment effects of rivastigmine on cognition, performance of daily living activities and behaviour in Alzheimer's disease in an outpatient geriatric setting. Frankfort SV; Appels BA; De Boer A; Tulner LR; Van Campen JP; Koks CH; Beijnen JH Int J Clin Pract; 2006 Jun; 60(6):646-54. PubMed ID: 16805746 [TBL] [Abstract][Full Text] [Related]
2. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Bullock R; Touchon J; Bergman H; Gambina G; He Y; Rapatz G; Nagel J; Lane R Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542 [TBL] [Abstract][Full Text] [Related]
3. Identification of responders and reactive domains to rivastigmine in Alzheimer's disease. Frankfort SV; Appels BA; de Boer A; Tulner LR; van Campen JP; Koks CH; Beijnen JH; Schmand BA Pharmacoepidemiol Drug Saf; 2007 May; 16(5):545-51. PubMed ID: 17109476 [TBL] [Abstract][Full Text] [Related]
4. [Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy]. Richard E; Walstra GJ; van Campen J; Vissers E; van Gool WA Ned Tijdschr Geneeskd; 2002 Jan; 146(1):24-7. PubMed ID: 11802333 [TBL] [Abstract][Full Text] [Related]
5. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease. Bartorelli L; Giraldi C; Saccardo M; Cammarata S; Bottini G; Fasanaro AM; Trequattrini A; Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. Alva G; Grossberg GT; Schmitt FA; Meng X; Olin JT Int J Geriatr Psychiatry; 2011 Apr; 26(4):356-63. PubMed ID: 21312297 [TBL] [Abstract][Full Text] [Related]
7. One-year treatment of Alzheimer's disease with acetylcholinesterase inhibitors: improvement on ADAS-cog and TMT A, no change or worsening on other tests. Borkowska A; Ziolkowska-Kochan M; Rybakowski JK Hum Psychopharmacol; 2005 Aug; 20(6):409-14. PubMed ID: 15991260 [TBL] [Abstract][Full Text] [Related]
8. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine. Riepe MW; Adler G; Ibach B; Weinkauf B; Tracik F; Gunay I Dement Geriatr Cogn Disord; 2007; 23(5):301-6. PubMed ID: 17356273 [TBL] [Abstract][Full Text] [Related]
9. Rivastigmine for cognitive impairment after spontaneous subarachnoid haemorrhage: a pilot study. Wong GK; Wong R; Mok V; Wong A; Fan D; Leung G; Chan A; Poon WS J Clin Pharm Ther; 2009 Dec; 34(6):657-63. PubMed ID: 20175798 [TBL] [Abstract][Full Text] [Related]
10. [Rivastigmine: a review of its clinical effectiveness]. Spiegel R Rev Neurol; 2002 Nov 1-15; 35(9):859-69. PubMed ID: 12436385 [TBL] [Abstract][Full Text] [Related]
11. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease. Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484 [TBL] [Abstract][Full Text] [Related]
12. [Presentation and stability of cognitive and noncognitive symptom patterns in patients with Alzheimer's disease. Disease course over a two-year period under constant treatment conditions with rivastigmine]. Wobrock T; Retz-Junginger P; Retz W; Supprian T; Rösler M Fortschr Neurol Psychiatr; 2003 Apr; 71(4):199-204. PubMed ID: 12677553 [TBL] [Abstract][Full Text] [Related]
13. Discontinuation of rivastigmine in routine clinical practice. Frankfort SV; Appels BA; de Boer A; Tulner LR; van Campen JP; Koks CH; Beijnen JH Int J Geriatr Psychiatry; 2005 Dec; 20(12):1167-71. PubMed ID: 16315150 [TBL] [Abstract][Full Text] [Related]
14. Identification of responders to rivastigmine: a prospective cohort study. Lemstra AW; Kuiper RB; Schmand B; van Gool WA Dement Geriatr Cogn Disord; 2008; 25(1):60-6. PubMed ID: 18033962 [TBL] [Abstract][Full Text] [Related]
15. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years. Small GW; Kaufer D; Mendiondo MS; Quarg P; Spiegel R Int J Clin Pract; 2005 Apr; 59(4):473-7. PubMed ID: 15853867 [TBL] [Abstract][Full Text] [Related]
16. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis. Dybicz SB; Keohane DJ; Erwin WG; McRae T; Shah SN Am J Geriatr Pharmacother; 2006 Jun; 4(2):154-60. PubMed ID: 16860262 [TBL] [Abstract][Full Text] [Related]
17. Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years. Farlow MR; Lilly ML; BMC Geriatr; 2005 Jan; 5():3. PubMed ID: 15659242 [TBL] [Abstract][Full Text] [Related]
18. A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study. Gauthier S; Juby A; Morelli L; Rehel B; Schecter R; Curr Med Res Opin; 2006 Nov; 22(11):2251-65. PubMed ID: 17076986 [TBL] [Abstract][Full Text] [Related]